logo
Climate change tripled deaths in European cities during recent heatwaves

Climate change tripled deaths in European cities during recent heatwaves

The National09-07-2025
Climate change tripled the number of heat-related deaths across European cities in the recent heatwaves, a rapid analysis by scientists has estimated.
Global warming, caused primarily by humans burning fossil fuels and cutting down forests, made the searing heat that gripped much of Europe in late June and early July much more intense, researchers found.
The heatwaves were up to 4°C hotter across cities compared to a world without climate change, the study from the World Weather Attribution group of researchers said.
And in the first rapid study to estimate the number of deaths linked to climate change in a heatwave, researchers found human-driven global warming was responsible for around 65 per cent of the deaths that occurred across 12 cities, including London, Paris, Madrid, Barcelona and Rome.
The scientists behind the study said that heatwaves were 'quietly devastating' and their research showed how dangerous climate change already was with just 1.3°C of warming, particularly for older and more vulnerable people.
They also said that their analysis focused on 12 cities, providing only a snapshot of the deaths linked to climate change-driven high temperatures across Europe, which may have reached into the tens of thousands.
The assessment focused on 10 days of heat from June 23 to July 2, when a 'heat dome' high pressure system over Europe trapped hot dry air and pushed up temperatures, as well as pulling hot air from North Africa, intensifying the heatwave.
The searing temperatures led schools to close in parts of France, outdoor working to be banned during the hottest parts of the day in Italy, raised the risk of wildfires, and triggered health alerts across many countries, including a red alert for Paris and amber alerts for London and many parts of England.
The researchers used weather data to assess the intensity of the heatwaves over their hottest five-day period in a world which has seen 1.3°C of warming and compared it the cooler pre-industrial climate.
The scientists also used existing research on the relationship between heat and the number of daily deaths in the cities to estimate the number of excess deaths due to the heatwaves and compared it to a 'counterfactual' of the numbers of deaths in heatwave temperatures without climate change.
The study, led by scientists at Imperial College London and the London School of Hygiene and Tropical Medicine (LSHTM), found around 1,500 of the 2,300 estimated heat deaths were the result of climate change – equating to a tripling of the number of deaths in the heatwave due to global warming.
Climate change was responsible for an estimated 171 excess deaths in London, 317 in Madrid and 235 in Paris, the study found.
Most of the deaths were in older age groups, the researchers said, highlighting the growing risk older people in Europe face from dying prematurely due to longer, hotter and more frequent heatwaves.
Dr Ben Clarke, researcher at the Centre for Environmental Policy at Imperial College London, said: 'Heatwaves don't leave a trail of destruction like wildfires or storms.
'Their impacts are mostly invisible, but quietly devastating – a change of just 2 or 3C can mean the difference between life and death for thousands of people.
'Our study shows how dangerous climate change already is with just 1.3C of warming.
'However, we could reach 3C this century, unless countries speed up the transition from fossil fuels to renewable energy.
'That would bring fiercer heatwaves to Europe, causing more deaths and placing greater pressure on health systems.'
Dr Pierre Masselot, research fellow at LSHTM, said: 'At the rate the world is warming, heatwaves are not going away and we have to prepare for their public health impacts.
'Cities can adapt by planting trees, reducing the space given to cars and caring for the most vulnerable.
'But ultimately, the best way to avoid dire consequences is to aggressively reduce greenhouse gases emissions.'
And Dr Friederike Otto, professor in climate science at the Centre for Environmental Policy at Imperial, said: 'This study highlights a simple fact: burning more oil, coal and gas will kill more people.
'The only way to stop European heatwaves from becoming even deadlier is to stop burning fossil fuels,' she warned.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Australia develops world-first foot and mouth vaccine to protect livestock
Australia develops world-first foot and mouth vaccine to protect livestock

Emirates 24/7

timea day ago

  • Emirates 24/7

Australia develops world-first foot and mouth vaccine to protect livestock

A team of scientists in New South Wales has developed the world's first mRNA vaccine designed to protect livestocks from foot-and-mouth disease (FMD), a highly contagious viral illness that poses a major threat to livestock. This FMD vaccine is an mRNA vaccine which is unique in that it is fully synthetic making it safer and much faster to produce. The development of this new vaccine is part of the Minns Government's $1 billion biosecurity plan, aimed at safeguarding New South Wales' US$8 billion livestock sector and reinforcing national food security. The vaccine has taken less than 18 months to develop and has cost about $2.5 million. Follow Emirates 24|7 on Google News.

Musk's Neuralink to test brain chips in clinical study in Great Britain
Musk's Neuralink to test brain chips in clinical study in Great Britain

Zawya

time5 days ago

  • Zawya

Musk's Neuralink to test brain chips in clinical study in Great Britain

Elon Musk's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, according to media reports, citing PitchBook. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)

Africa Centres for Disease Control and Prevention (Africa CDC) and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa
Africa Centres for Disease Control and Prevention (Africa CDC) and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa

Zawya

time5 days ago

  • Zawya

Africa Centres for Disease Control and Prevention (Africa CDC) and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa

The Africa Centres for Disease Control and Prevention (Africa CDC) and the European Commission today announced the launch of the Partnership to Accelerate Mpox Testing and Sequencing in Africa (PAMTA), a landmark initiative to boost diagnostics and outbreak response capabilities in Mpox-affected African countries. Co-funded under the EU4Health 2024 Work Programme, PAMTA reflects the growing momentum of Africa–EU health cooperation and aims to reinforce the continent's resilience against current and future health threats. The initiative will accelerate testing, sequencing, capacity building, and local manufacturing efforts for mpox and other priority pathogens across Africa through a €9.4 million to Africa CDC and the African Society for Laboratory Medicine (ASLM), managed by the European Health and Digital Executive Agency (HaDEA). The project officially began on 1 June 2025 and will be implemented over three years. Africa CDC Director General, H.E. Dr Jean Kaseya, welcomed the initiative as a timely and strategic intervention to close the diagnostic gap for Mpox and other outbreaks in Africa. 'This partnership reflects our commitment to working with trusted partners to build agile and self-reliant public health systems across Africa. Together with the EU and our technical partners, we are setting a new benchmark for outbreak detection and response.' The PAMTA initiative focuses on four key objectives: scaling up Mpox testing with the goal of supporting over 150,000 tests across the continent; strengthening genomic sequencing capacity to track viral evolution and spread; building human resource capacity in molecular diagnostics, genomics, bioinformatics and data interpretation; and promoting the production and validation of locally developed testing kits within Africa. 'PAMTA marks a historic milestone as the first initiative jointly signed between the European Commission and Africa CDC,' said Deputy Head of DG HERA, Laurent Muschel. 'Building on HERA's earlier donation of Mpox vaccines, this action enables a critical next step: strengthening diagnostic capacities as part of a broader medical countermeasures approach. It reflects our shared commitment to reinforcing epidemic preparedness across Africa — from vaccines to diagnostics, from innovation to manufacturing. This action shows that, together, the African Union and the European Union can deliver tangible results to protect lives.' The launch of PAMTA builds on broader efforts by the EU and its partners to address the Mpox outbreak. By mid-2025, more than 600,000 vaccine doses had been delivered to African countries through HERA and Team Europe. Simultaneously, research initiatives such as MPX-RESPONSE and EDCTP3 continue to explore new therapeutic options, while the Africa Pathogen Genomics Initiative (PGI)—also funded through EU4Health—is enhancing public health laboratory networks and genomic surveillance across the continent through public private partnerships. PAMTA marks a significant milestone in EU–Africa collaboration for health resilience. By supporting comprehensive diagnostics and fostering local innovation, the initiative is helping to lay a strong foundation for Africa's long-term pandemic preparedness and response capabilities. Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store